| Dr Jennifer Diane Wetherald, DO | |
|
301 Brundage Ln, Bakersfield, CA 93304 | |
| (661) 323-6086 | |
| (661) 324-6301 |
| Full Name | Dr Jennifer Diane Wetherald |
|---|---|
| Gender | Female |
| Speciality | Obstetrics/gynecology |
| Experience | 9 Years |
| Location | 301 Brundage Ln, Bakersfield, California |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1407249733 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207V00000X | Obstetrics & Gynecology | 20A17315 (California) | Primary |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Rural Health Group Inc | 9739090226 | 46 |
News Archive
Delivering an effective therapeutic payload to specific target cells with few adverse effects is considered by many to be the holy grail of medical research. A new Tel Aviv University study explores a biological approach to directing nanocarriers loaded with protein "game changers" to specific cells.
For patients at the end of life, palliative care can prolong survival and improve the quality of life for patients with a life-threatening illness and for their families.
Researchers at Moffitt Cancer Center and colleagues have demonstrated that the inhibition of signal transducer and activator of transcription 3 (STAT3) in mouse models of mantle cell lymphoma (MCL), an aggressive and incurable subtype of B-cell non-Hodgkin lymphoma that becomes resistant to treatment, can harness the immune system to eradicate residual malignant cells responsible for disease relapse.
Findings of a clinical trial reported at SNM's 57th Annual Meeting indicate that a new molecular imaging agent could improve diagnosis of recurrent prostate cancer and determine the best possible course of treatment for patients.
If all goes according to plan, Penn State University students who opt for an on-campus experience this fall will start in-person classes on Aug. 24 under the banner of a "Mask Up or Pack Up" campaign.
› Verified 2 days ago
| Entity Name | Rural Health Group Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1689626178 PECOS PAC ID: 9739090226 Enrollment ID: O20050708000124 |
News Archive
Delivering an effective therapeutic payload to specific target cells with few adverse effects is considered by many to be the holy grail of medical research. A new Tel Aviv University study explores a biological approach to directing nanocarriers loaded with protein "game changers" to specific cells.
For patients at the end of life, palliative care can prolong survival and improve the quality of life for patients with a life-threatening illness and for their families.
Researchers at Moffitt Cancer Center and colleagues have demonstrated that the inhibition of signal transducer and activator of transcription 3 (STAT3) in mouse models of mantle cell lymphoma (MCL), an aggressive and incurable subtype of B-cell non-Hodgkin lymphoma that becomes resistant to treatment, can harness the immune system to eradicate residual malignant cells responsible for disease relapse.
Findings of a clinical trial reported at SNM's 57th Annual Meeting indicate that a new molecular imaging agent could improve diagnosis of recurrent prostate cancer and determine the best possible course of treatment for patients.
If all goes according to plan, Penn State University students who opt for an on-campus experience this fall will start in-person classes on Aug. 24 under the banner of a "Mask Up or Pack Up" campaign.
› Verified 2 days ago
| Entity Name | Rural Health Group Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1598253734 PECOS PAC ID: 9739090226 Enrollment ID: O20181226000347 |
News Archive
Delivering an effective therapeutic payload to specific target cells with few adverse effects is considered by many to be the holy grail of medical research. A new Tel Aviv University study explores a biological approach to directing nanocarriers loaded with protein "game changers" to specific cells.
For patients at the end of life, palliative care can prolong survival and improve the quality of life for patients with a life-threatening illness and for their families.
Researchers at Moffitt Cancer Center and colleagues have demonstrated that the inhibition of signal transducer and activator of transcription 3 (STAT3) in mouse models of mantle cell lymphoma (MCL), an aggressive and incurable subtype of B-cell non-Hodgkin lymphoma that becomes resistant to treatment, can harness the immune system to eradicate residual malignant cells responsible for disease relapse.
Findings of a clinical trial reported at SNM's 57th Annual Meeting indicate that a new molecular imaging agent could improve diagnosis of recurrent prostate cancer and determine the best possible course of treatment for patients.
If all goes according to plan, Penn State University students who opt for an on-campus experience this fall will start in-person classes on Aug. 24 under the banner of a "Mask Up or Pack Up" campaign.
› Verified 2 days ago
| Entity Name | Rural Health Group Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1871081000 PECOS PAC ID: 9739090226 Enrollment ID: O20190103000875 |
News Archive
Delivering an effective therapeutic payload to specific target cells with few adverse effects is considered by many to be the holy grail of medical research. A new Tel Aviv University study explores a biological approach to directing nanocarriers loaded with protein "game changers" to specific cells.
For patients at the end of life, palliative care can prolong survival and improve the quality of life for patients with a life-threatening illness and for their families.
Researchers at Moffitt Cancer Center and colleagues have demonstrated that the inhibition of signal transducer and activator of transcription 3 (STAT3) in mouse models of mantle cell lymphoma (MCL), an aggressive and incurable subtype of B-cell non-Hodgkin lymphoma that becomes resistant to treatment, can harness the immune system to eradicate residual malignant cells responsible for disease relapse.
Findings of a clinical trial reported at SNM's 57th Annual Meeting indicate that a new molecular imaging agent could improve diagnosis of recurrent prostate cancer and determine the best possible course of treatment for patients.
If all goes according to plan, Penn State University students who opt for an on-campus experience this fall will start in-person classes on Aug. 24 under the banner of a "Mask Up or Pack Up" campaign.
› Verified 2 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Jennifer Diane Wetherald, DO Po Box 1559, Bakersfield, CA 93302-1559 Ph: (661) 635-3050 | Dr Jennifer Diane Wetherald, DO 301 Brundage Ln, Bakersfield, CA 93304 Ph: (661) 323-6086 |
News Archive
Delivering an effective therapeutic payload to specific target cells with few adverse effects is considered by many to be the holy grail of medical research. A new Tel Aviv University study explores a biological approach to directing nanocarriers loaded with protein "game changers" to specific cells.
For patients at the end of life, palliative care can prolong survival and improve the quality of life for patients with a life-threatening illness and for their families.
Researchers at Moffitt Cancer Center and colleagues have demonstrated that the inhibition of signal transducer and activator of transcription 3 (STAT3) in mouse models of mantle cell lymphoma (MCL), an aggressive and incurable subtype of B-cell non-Hodgkin lymphoma that becomes resistant to treatment, can harness the immune system to eradicate residual malignant cells responsible for disease relapse.
Findings of a clinical trial reported at SNM's 57th Annual Meeting indicate that a new molecular imaging agent could improve diagnosis of recurrent prostate cancer and determine the best possible course of treatment for patients.
If all goes according to plan, Penn State University students who opt for an on-campus experience this fall will start in-person classes on Aug. 24 under the banner of a "Mask Up or Pack Up" campaign.
› Verified 2 days ago
Dr. Lynous Willard Hall, M.D. Obstetrics & Gynecology Medicare: Accepting Medicare Assignments Practice Location: 625 34th St Ste 100, Bakersfield, CA 93301 Phone: 833-678-2781 Fax: 661-368-0618 | |
Thomas Wayne Moxley, M.D. Obstetrics & Gynecology Medicare: Medicare Enrolled Practice Location: 1700 Mount Vernon Ave, Kern Medical Center, Bakersfield, CA 93306 Phone: 661-326-2236 | |
Rebecca Rivera, M.D. Obstetrics & Gynecology Medicare: Accepting Medicare Assignments Practice Location: 2525 Eye St, Suite 110, Bakersfield, CA 93301 Phone: 661-637-0137 Fax: 661-637-0177 | |
Leonard Perez, M.D. Obstetrics & Gynecology Medicare: Accepting Medicare Assignments Practice Location: 2005 17th St, Bakersfield, CA 93301 Phone: 661-322-6700 Fax: 661-322-6707 | |
Dr. Julia Canders, MD Obstetrics & Gynecology Medicare: Medicare Enrolled Practice Location: 1700 Mount Vernon Ave, Bakersfield, CA 93306 Phone: 661-326-2237 Fax: 661-326-2235 | |
Dr. John R Owens, M.D Obstetrics & Gynecology Medicare: Medicare Enrolled Practice Location: 4000 Physicians Blvd, Ste 211, Bakersfield, CA 93301 Phone: 661-327-3821 Fax: 661-327-2061 | |
Debra Lee Stewart, D.O. Obstetrics & Gynecology Medicare: Medicare Enrolled Practice Location: 625 34th St Ste 100, Bakersfield, CA 93301 Phone: 833-678-2781 Fax: 661-800-4318 |